FEV transcription factor, ETS family memberGenealiases: HSRNAFEV · PET-1
Q-omics provides the consensus-scored FEV profile across patient tissues and cancer cell-line models. FEV expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FEV is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, FEV RNA expression shows 10,120 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where FEV shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FEV — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FEV survival associations across molecular data types. FEV RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FEV RNA expression–survival associations across cancer types. High FEV expression shows unfavorable associations in LUAD, UCEC, LUSC, KIRP and THCA, but favorable associations in PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LUAD as the clearest survival context for FEV RNA expression.
This table summarizes FEV tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FEV. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FEV shows lower tumor expression in COAD, UCEC, READ, BLCA and BRCA and higher tumor expression in PRAD. The COAD box plot shows higher FEV RNA expression in normal versus tumor tissue (log2 FC = −1.971, t-test p < 0.001).
This table shows molecular features associated with FEV in patient tissues and cancer cell lines. In patient samples, FEV shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FEV RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
